-
Focus: Drugs most vulnerable to counterfeiting and diversion
-
Final: Very minor changes from draft CPG
-
Factors to consider by FDA field personnel regarding where they should target their enforcement efforts and prioritize resources.
-
Risk-based focus with examples
-
High value in US market
-
Prior history of counterfeiting or diversion
-
Reasonable probability for new drugs
-
-
Other violations of law
-
NOT an excuse for non-compliance